NEW YORK (GenomeWeb News) — Minerva Biotechnologies has non-exclusively licensed Osmetech’s self-assembling monolayer technology for use with its proprietary nanoparticle technology, Osmetech said today.
Osmetech said Minerva will use the SAM technology to study signal enhancement, drug design, drug screening, and functional proteomics.
Osmetech exclusively licensed the technology from Harvard University a decade ago. The IP was invented in part by Minerva founder and CSO Cynthia Bamdad.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.